One Two
Kontakt:

An der Immenburg 4 (Stadtplan)

53121 Bonn

Telefon: 0228-732698

E-Mail: [Email protection active, please enable JavaScript.]

Homepage: www.pharma.uni-bonn.de

 
Sie sind hier: Startseite AK Hansen Publikationen

Publikationen

Dieses Verzeichnis enthält folgenden Referenzen zu Publikationen (sortiert nach Erscheinungsjahr und Autor):

Es befinden sich 67 Einträge in diesem Literaturverzeichnis.

Bhatia, S, Spanier, L, Bickel, D, Dienstbier, N, Woloschin, V, Vogt, M, Pols, H, Lungerich, B, Reiners, J, Aghaallaei, N, Diedrich, D, Frieg, B, Schliehe-Diecks, J, Bopp, B, Lang, F, Gopalswamy, M, Loschwitz, J, Bajohgli, B, Skokowa, J, Borkhardt, A, Hauer, J, Hansen, FK, Smits, SHJ, Jose, J, Gohlke, H, and Kurz, T (2022).
Development of a First-in-Class Small-Molecule Inhibitor of the C-Terminal Hsp90 Dimerization
ACS Central Science, 90:DOI: 10.1021/acscentsci.2c00013--DOI: 10.1021/acscentsci.2c00013.

Chu, K, Lee, H, Pflieger, M, Fischer, F, Asfaha, Y, Alves Avelar, LA, Skerhut, A, Kassack, MU, Hansen, FK, Schöler, A, Kurz, T, Kim, M, Moon, E, and Quan, F (2022).
Antiproliferation and Antiencystation Effect of Class II Histone Deacetylase Inhibitors on Acanthamoeba castellanii
ACS Infectious Diseases, 8(2):271–279.

Clauß, O, Schäker-Hübner, L, Wenzel, B, Toussaint, M, Deuther-Conrad, W, Gündel, D, Teodoro, R, Dukić-Stefanović, S, Ludwig, F, Kopka, K, Brust, P, Hansen, FK, and Scheunemann, M (2022).
Development and Biological Evaluation of the First Highly Potent and Specific Benzamide-Based Radiotracer [18F]BA3 for Imaging of Histone Deacetylases 1 and 2 in Brain
Pharmaceuticals, 15(3):324.

Keuler, T, König, B, Bückreiß, N, Kraft, FB, König, P, Steinebach, C, Bendas, G, and Hansen, FK (2022).
Development of the first non-hydroxamate selective HDAC6 degraders
ChemRxiv:DOI: 10.26434/chemrxiv--2022-3rhqf.

Schäker‐Hübner, L, Haschemi, R, Büch, T, Kraft, FB, Brumme, B, Schöler, A, Jenke, R, Meiler, J, Aigner, A, Bendas, G, and Hansen, FK (2022).
Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
ChemMedChem, 17(9):e202100755--e202100755.

Sinatra, L, Yang, J, Schliehe-Diecks, J, Dienstbier, N, Vogt, M, Gebing, P, Bachmann, LM, Sönnichsen, M, Lenz, T, Stühler, K, Schöler, A, Borkhardt, A, Bhatia, S, and Hansen, FK (2022).
Solid-phase synthesis of cereblon-recruiting selective histone deacetylase 6 degraders (HDAC6 PROTACs) with anti-leukemic activity
ChemRxiv:DOI: 10.26434/chemrxiv--2022-dntx4.

Vogelmann, A, Jung, M, Hansen, FK, and Schiedel, M (2022).
Comparison of Cellular Target Engagement Methods for the Tubulin Deacetylases Sirt2 and HDAC6: NanoBRET, CETSA, Tubulin Acetylation, and PROTACs
ACS Pharmacology & Translational Science, 5(2):138--140.

von Bredow, L, Schäfer, TM, Hogenkamp, J, Tretbar, M, Stopper, D, Kraft, FB, Schliehe-Diecks, J, Schöler, A, Borkhardt, A, Bhatia, S, Held, J, and Hansen, FK (2022).
Synthesis, Antiplasmodial, and Antileukemia Activity of Dihydroartemisinin–HDAC Inhibitor Hybrids as Multitarget Drugs
Pharmaceuticals, 15(3):333.

Alves Avelar, LA, Schrenk, C, Sönnichsen, M, Hamacher, A, Hansen, FK, Schliehe-Diecks, J, Borkhardt, A, Bhatia, S, Kassack, MU, and Kurz, T (2021).
Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors
European Journal of Medicinal Chemistry, 211:113095.

Bhatia, S, Hansen, FK, and Schiedel, M (2021).
Call for Papers: “Epigenetics 2.0”—A Joint Virtual Special Issue on Epigenetics
ACS Pharmacology & Translational Science, 4(4):1262–1263.

Jenke, R, Reßing, N, Hansen, FK, Aigner, A, and Büch, T (2021).
Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives
Cancers, 13(4):634.

Mackwitz, MK, Hesping, E, Eribez, K, Schöler, A, Antonova-Koch, Y, Held, J, Winzeler, EA, Andrews, KT, and Hansen, FK (2021).
Investigation of the in vitro and in vivo efficacy of peptoid-based HDAC inhibitors with dual-stage antiplasmodial activity
European Journal of Medicinal Chemistry, 211:113065.

Müller, CE, Hansen, FK, Gütschow, M, Lindsley, CW, and Liotta, D (2021).
New Drug Modalities in Medicinal Chemistry, Pharmacology, and Translational Science: Joint Virtual Special Issue by Journal of Medicinal Chemistry , ACS Medicinal Chemistry Letters , and ACS Pharmacology & Translational Science
Journal of Medicinal Chemistry, 64(19):13935–13936.

OKUBO, K, ISONO, M, ASANO, T, REßING, N, SCHULZ, WA, HANSEN, FK, and SATO, A (2021).
Ubiquitin-proteasome System Is a Promising Target for Killing Cisplatin-resistant Bladder Cancer Cells
Anticancer Research, 41(6):2901–2912.

Okubo, K, Reßing, N, Schulz, WA, Hansen, FK, Asano, T, and Sato, A (2021).
The Dual Histone Deacetylase-Proteasome Inhibitor RTS-V5 Acts Synergistically With Ritonavir to Induce Endoplasmic Reticulum Stress in Bladder Cancer Cells
Anticancer Research, 41(12):5987--5996.

Pflieger, M, Sönnichsen, M, Horstick‐Muche, N, Yang, J, Schliehe‐Diecks, J, Schöler, A, Borkhardt, A, Hamacher, A, Kassack, MU, Hansen, FK, Bhatia, S, and Kurz, T (2021).
Oxa Analogues of Nexturastat A Demonstrate Improved HDAC6 Selectivity and Superior Antileukaemia Activity
ChemMedChem, 16(11):1799–1804.

Schäker-Hübner, L, Warstat, R, Ahlert, H, Mishra, P, Kraft, FB, Schliehe-Diecks, J, Schöler, A, Borkhardt, A, Breit, B, Bhatia, S, Hügle, M, Günther, S, and Hansen, FK (2021).
4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads
Journal of Medicinal Chemistry, 64(19):14620–14646.

Selg, C, Schöler, A, Schliehe-Diecks, J, Hanl, M, Sinatra, L, Borkhardt, A, Sárosi, MB, Bhatia, S, Hey-Hawkins, E, and Hansen, FK (2021).
Borinostats: solid-phase synthesis of carborane-capped histone deacetylase inhibitors with a tailor-made selectivity profile
Chemical Science, 12(35):11873–11881.

Sinatra, L, Kolano, L, Icker, M, Fritzsche, SR, Volke, D, Gockel, I, Thieme, R, Hoffmann, R, and Hansen, FK (2021).
Hybrid Peptides Based on α‐Aminoxy Acids as Antimicrobial and Anticancer Foldamers
ChemPlusChem, 86(6):827–835.

Benedetti, R, Conte, M, Dell'Aversana, C, Hansen, FK, and Zwergel, C (2020).
Editorial: Chemical Innovative Approaches in Cancer Molecular Medicine and Translational Clinical Research
Frontiers in Chemistry, 8(September):3–4.

Friedrich, A, Assmann, AS, Schumacher, L, Stuijvenberg, JV, Kassack, MU, Schulz, WA, Roos, WP, Hansen, FK, Pflieger, M, Kurz, T, and Fritz, G (2020).
In vitro assessment of the genotoxic hazard of novel hydroxamic acid-and benzamide-type histone deacetylase inhibitors (HDACi)
International Journal of Molecular Sciences, 21(13):1–21.

Moita, AJ, Bandolik, JJ, Hansen, FK, Kurz, T, Hamacher, A, and Kassack, MU (2020).
Priming with hdac inhibitors sensitizes ovarian cancer cells to treatment with cisplatin and hsp90 inhibitors
International Journal of Molecular Sciences, 21(21):1–22.

Reßing, N, Sönnichsen, M, Osko, JD, Schöler, A, Schliehe-Diecks, J, Skerhut, A, Borkhardt, A, Hauer, J, Kassack, MU, Christianson, DW, Bhatia, S, and Hansen, FK (2020).
Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups
Journal of Medicinal Chemistry, 63(18):10339–10351.

Sinatra, L, Bandolik, JJ, Roatsch, M, Sönnichsen, M, Schoeder, CT, Hamacher, A, Schöler, A, Borkhardt, A, Meiler, J, Bhatia, S, Kassack, MU, and Hansen, FK (2020).
Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual‐Targeting HDAC Inhibitors and HDAC Degraders (PROTACs)
Angewandte Chemie International Edition, 59(50):22494–22499.

Erdeljac, N, Bussmann, K, Schöler, A, Hansen, FK, and Gilmour, R (2019).
Fluorinated Analogues of the Histone Deacetylase Inhibitor Vorinostat (Zolinza): Validation of a Chiral Hybrid Bioisostere, BITE
ACS Medicinal Chemistry Letters, 10(9):1336–1340.